By HealthDataConsortium.org Research Team
Short answer: CBD itself is not intoxicating — it doesn’t produce the “high” associated with THC. That much is well established. But it’s not the full answer a careful shopper needs, because the product in your hand may not be CBD alone, and “nonintoxicating” is a narrower promise than it sounds. Here’s what the label can and can’t tell you, and what’s worth checking before you buy or use a CBD product.
Can a Product Labeled “CBD” Contain THC?
Yes — and legally, it often does.
Under the 2018 Farm Bill, hemp is federally defined as cannabis containing no more than 0.3% THC by dry weight. Products derived from hemp that fall under that threshold can legally be sold and labeled as “CBD” products, even though the law doesn’t require them to contain zero THC. A product can be fully compliant with federal hemp law and still contain measurable trace THC.
This shows up in testing. A peer-reviewed study in JAMA Network Open analyzed 105 hemp-derived CBD topical products (creams and balms) purchased online and in national retail stores. THC was detected in 37 of them — about 35% of the sample. All were within the legal 0.3% limit, but the labeling often didn’t say so: 11% of the THC-positive products were explicitly marketed as “THC-free,” and roughly half made no mention of THC on the label at all. The same study found CBD content itself was frequently off — only 24% of products that listed a CBD amount were within 10% of that stated figure.
That data is specific to topical products; label accuracy may differ for oils, tinctures, gummies, or vapes, which weren’t part of this particular study. The broader pattern it points to still holds across the category: a “CBD” or “THC-free” label is a marketing claim, not a lab result, and it isn’t always reliable on its own.
If THC content matters to you — for a drug screening, a sensitivity, or any other reason — the label alone may not answer the question. A current, batch-specific Certificate of Analysis (COA) from third-party lab testing is the more reliable source, when one is available.
Does Nonintoxicating Mean No Impairment or Interactions?
No. This is where casual CBD marketing tends to get imprecise, so it’s worth separating the two claims.
“Nonintoxicating” describes one specific thing: CBD doesn’t produce the euphoric, perception-altering “high” that THC does. It does not mean CBD has no measurable effect on the body, and it does not mean CBD is risk-free when combined with other substances or medications. Two verified points worth knowing:
- Liver enzyme changes. In clinical trials supporting Epidiolex — the only FDA-approved prescription CBD drug — elevated liver enzymes occurred in 8–16% of subjects taking the drug, compared with about 3% of subjects on placebo. Elevated liver enzymes are a marker doctors use to flag possible liver stress. Important limit: this data comes from a purified, prescription-strength CBD product used under medical supervision — not an over-the-counter gummy or tincture at a typical consumer dose. It doesn’t tell us the exact risk at lower OTC doses, but it does establish that CBD is pharmacologically active enough to affect liver function, which undercuts any “it’s just a supplement, it can’t do anything” assumption.
- Drug-drug interactions. CBD has the capacity to inhibit cytochrome P450 enzymes and UGT enzymes — the same liver enzyme systems that metabolize a large share of commonly prescribed medications. That creates potential for CBD to change how other drugs are processed in the body. A federally registered clinical trial is currently underway specifically to measure these interaction risks at consumer-level CBD doses — which is itself a sign that the real-world clinical significance of many CBD drug interactions is still being worked out, not yet fully mapped.
Put together: “won’t get you high” and “safe to combine with anything” are two separate claims, and only the first one is well established. The second depends on what else you’re taking, at what dose, and what’s actually in the specific product — which circles back to the labeling problem above.
A Framework for Reading Any CBD Label
This isn’t a verdict on CBD as a category — it’s a way to work through the specific product in front of you.
- Does the product disclose a batch-specific Certificate of Analysis (COA)?
- What to look for: a third-party lab report, not just brand marketing copy
- The limit: a COA reflects one tested batch, not every unit on the shelf
- Worth checking: does the COA’s batch number and date match what’s on your product?
- Does the label say “THC-free,” “non-detect,” or simply omit THC?
- What to look for: a lab-tested THC result, not a marketing claim
- The limit: published testing has found “THC-free” claims aren’t always accurate, even when any THC present stays under the legal 0.3% threshold
- Worth checking: what detection limit did the lab use — would trace amounts even register?
- Are you currently taking a prescription medication, especially one processed by the liver?
- What to look for: whether that specific medication has published CBD-interaction data
- The limit: interaction research is still incomplete for many specific drug combinations
- Worth checking: this is a pharmacist or prescriber question, not something a product label can answer
Where This Leaves a Shopper
CBD won’t get you high — that part holds up. But “nonintoxicating” is a narrower claim than “risk-free” or “THC-free,” and the label by itself doesn’t confirm THC content, exact CBD dose, or how a given product might interact with anything else you’re taking. A batch-specific COA closes most of that gap when one is available; a conversation with a pharmacist closes the rest, particularly if you’re on any prescription medication.
If you’re also comparing specific products side by side, our Golden Touch Fusion CBD Gummies page covers one product’s claims and pricing in more depth.
